CS Paper Radar

VINCENT: Validated Interaction Network for Cross-drug Explanation of Therapeutics

Fan-Sheng Chuang, Xuchen Li, Yujing Bian, Kaixiong Zhou

cs.LG cs.AI ·submitted 2026-08-26 14:18 UTC · v1

Abstract

Drug synergy prediction estimates whether two drugs produce a stronger joint effect than expected from their individual activities. For drug combination discovery, a single synergy score is often not enough: researchers also need to know which molecular regions jointly drive the prediction. We study motif-pair synergy explanation, which identifies pairs of chemically coherent regions, one from each drug, that jointly contribute to predicted synergy. Existing interpretable synergy models expose atom- or substructure-level signals, but their explanations are built into the predictor architecture, and none validates cross-drug region scores under repeated perturbations or feeds that evidence back to refine the explanation. A reliable motif-pair explanation should instead be chemically coherent, perturbation-stable, and aligned with predictor behavior. We introduce VINCENT (Validated Interaction Network for Cross-drug Explanation of Therapeutics), a post-training framework for a fixed interaction-aware synergy predictor. VINCENT extracts atom-pair evidence from attention and gradient signals, groups atoms into chemically coherent motifs, and validates candidate motif pairs through repeated local perturbations. The validated evidence is fed back to refine motif assignments, yielding explanations that satisfy these three criteria. On a 25-pair literature-annotated subset, VINCENT achieves a mean motif recall of 0.826 (95% CI: 0.78-0.87), compared with 0.49-0.66 for baselines. Across all 71 test pairs, its validated interaction scores yield a TP/TN separation of 3.36. These results show that closed-loop perturbation validation recovers literature-supported molecular regions more accurately than existing alternatives while producing cross-drug interaction scores that better reflect predictor behavior.

Comment
18 pages, 4 figures

Closest papers

Nearest neighbours by meaning across the whole index.

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-09-02 ·Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao +6 more
code/data similarity 0.74
Abstract

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI

0.28

BiGSyn: A Bi-Level Heterogeneous Graph Contrastive Learning Framework for Interpretable Drug Synergy Prediction

cs.AI ·2026-11-16 ·Senquan Wang, Hui Fang, Haoran Nan, Xingwei Wang, Qiang He
publishedbenchmark similarity 0.73
Abstract · 2026 IEEE International Conference on Data Mining (ICDM 2026)

Drug combination therapy has become a mainstream of modern medicine, with the potential to enhance efficacy, reduce toxicity, and overcome drug resistance. However, identifying synergistic drug combinations remains challenging, as it requires modeling complex interactions across multiple biological scales---from atom-level molecular structures to entity-level relations in biological networks. Existing approaches typically model these levels in isolation, overlooking complementary signals and long-range dependencies. To address these limitations, we propose BiGSyn, a Bi-level heterogeneous Graph contrastive learning framework for drug Synergy prediction. Specifically, BiGSyn leverages heterogeneous graph transformers to extract high-order dependencies from molecular graphs and biological networks, and introduces a bi-level contrastive learning objective to bridge the cross-level semantic gap. Extensive experiments on two benchmark datasets show that BiGSyn consistently outperforms state-of-the-art baselines. Moreover, its attention mechanism highlights key molecular substructures and biological interactions driving synergy, providing interpretable insights.

0.18

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.71
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31

Bison: Cross-Dataset Learning for Unseen-Compound Perturbation Prediction

cs.LG cs.AI ·2026-09-26 ·Yunfan Liu, Kasra Ghorbani, Yufei Huang, Zicheng Liu, Jiangbin Zheng +4 more
benchmark similarity 0.70
Abstract

Predicting transcriptional responses to unseen compounds is limited by fragmented chemical coverage and heterogeneous experimental platforms and gene panels. To assess molecular generalization across these settings, we build on Chem-PerturBridge to benchmark eight datasets with 16,771 compounds, withholding test compounds from every training dataset. This comparison reveals that high overall response agreement can coexist with weak prediction of drug-specific differences, despite reproducible signals across repeated measurements. To exploit complementary chemical supervision while targeting these differences, we introduce Bison: a shared gene representation connects native panels, while two discrete diffusion models compose context-dependent responses with molecular deviations learned through matched drug-contrast supervision. A single Bison model jointly trained across all eight datasets achieves the highest mean overall-response and drug-contrast Pearson correlations on the full benchmark in comparison with 11 methods trained independently per dataset. Compared with dataset-specific training of the same architecture, joint training increases mean drug-contrast correlation by 27.4\%, with gains across all eight datasets and improvements in overall response prediction. These results demonstrate how matched drug contrasts turn complementary screens into shared molecular supervision for unseen-drug response prediction while preserving native gene measurements.

0.14

Chemical and geometric representation fidelity improves drug--target affinity prediction

cs.AI q-bio.BMcs.LGstat.ML ·2026-09-02 ·Yixiao Li, Yining Qian, Yefan Chen, Zenghui Chen, Jiayue Sun +3 more
benchmark similarity 0.70
Abstract · 21 pages, 10 figures

Predicting drug--target binding affinity (DTA) requires models to distinguish subtle chemical and structural determinants underlying molecular recognition. Although recent approaches increasingly incorporate richer drug and protein information, such information may be compressed, homogenized or discretized during representation construction, causing affinity-relevant distinctions to be lost before interaction modelling. We hypothesized that this representation-stage information loss constitutes an upstream bottleneck that cannot be reliably overcome by increasingly complex interaction predictors. To test this hypothesis, we developed ReGeoDTA, a representation-preserving framework that maintains affinity-relevant chemical heterogeneity in molecular representations and continuous geometric relationships in protein structures. Across three benchmark datasets, ReGeoDTA consistently improved affinity prediction, and the proposed representation-preserving strategies retained their benefits across diverse DTA architectures. Controlled representation degradation progressively reduced predictive performance, whereas increasing downstream predictor complexity failed to recover information lost during representation construction. These findings identify representation fidelity as an upstream design principle for accurate and generalizable drug--target affinity prediction, with potential implications for computational compound prioritization.

0.23

Fragment-Level Graph Encoding for Interpretable Molecular Property Prediction

cs.LG stat.ML ·2026-10-21 ·Rafael Lopes Almeida, Ina Pöhner
publishedcode/data similarity 0.69
Abstract · 12 pages, 3 figures, 6-page appendices, to be published in Proceedings of the 8th Northern Lights Deep Learning Conference (NLDL), 2027. For…

Graph neural networks (GNNs) are among the standard tools for molecular property prediction, but the atom-level explanations of their predictions are hard for medicinal chemists to act on. We propose a change of input representation rather than a new model: molecules are encoded as fragment-level graphs from BRICS decomposition, where each node is a synthetically meaningful fragment whose features are the element-wise sum of its atoms' features. Because only the representation changes, any message-passing GNN and any post-hoc attribution method produces explanations at the resolution of functional groups instead of single atoms. Across four architectures, four prediction tasks, and two explainers under scaffold splits, fragment-level encoding matches atom-level test accuracy on roughly five-fold smaller graphs. Integrated-Gradients attributions recover known pharmacophores above chance on two enzyme targets, namely BACE at 1.5 times the chance rate, and PTR1 at 3.2 times. A like-for-like comparison against an aggregated atom-level baseline shows that post-hoc aggregation is not a stable substitute: its BACE hit rate range both exceeds and falls below the fragment model's hit rate depending on two arbitrary aggregation choices, whereas fragment-level training yields a single convention-free attribution at no predictive cost. The code is available at: https://github.com/4D-Lab/frame

0.36

SpecOpt: Contact-Diff Reasoning for Agentic Molecule Optimization Toward Binding Specificity

cs.AI ·2026-09-18 ·Thao Nguyen, Heng Ji
benchmark similarity 0.69
Abstract

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

0.08

Drug-Target Interaction Prediction via Hierarchical Sequential Cross-Attention over Chemical and Protein Language Models

cs.LG cs.AI ·2026-09-28 ·Khadidja Henni, Hamza Abdelali, Abdelkrim Aries, Neila Mezghani, Brigitte Vannier +2 more
similarity 0.69
Abstract

Predicting Drug-Target Interactions~(DTIs) is a central task in computational drug discovery, with direct applications in virtual screening, drug repurposing, and therapeutic candidate prioritization. Although recent deep learning methods have improved DTI prediction, many sequence-based models still process drugs and proteins independently and only combine their representations at a late prediction stage. This limits their ability to explicitly model cross-molecular dependencies between chemical substructures and protein sequence regions. In this paper, we propose a sequence-only DTI prediction architecture that combines two pre-trained language models, ChemBERTa for drug SMILES strings and ESM-2 for protein amino acid sequences, with a hierarchical interaction module. The proposed model first extracts contextual representations using pre-trained encoders, then applies 1D convolutional layers to condense local sequence patterns, followed by a sequential bidirectional cross-attention mechanism inspired by the induced-fit view of molecular recognition. Finally, attention-based pooling constructs fixed-size interaction-aware vectors for binary prediction. Experiments on BIOSNAP, Davis, and BindingDB show that the proposed model achieves the best performance on BIOSNAP, matches the best AUROC on Davis, and remains competitive on BindingDB while using only 25.2 million trainable parameters. Ablation results confirm the contribution of both the CNN and cross-attention modules, and cold-start experiments indicate promising generalization to unseen proteins and drugs.

0.12